Update examples for new UI

ademirjs · Sep 9, 2014 · f5738c3 · f5738c3
1 parent 6328722
commit f5738c3
Show file tree

Hide file tree

Showing 6 changed files with 44 additions and 9 deletions.
diff --git a/examples/fava.json b/examples/fava.json
@@ -1,9 +1,12 @@
 {
   "title" : "Fava et al, 2002 BR",
+  "description": "Based on Fava et al. (2002), \"Acute Efficacy of Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder Including Effects of Baseline Insomnia\".",
   "criteria" : {
     "ham-d-responders" : {
       "title" : "HAM-D Responders",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
+      "description": "Responders on the HAM-D rating scale",
       "pvf" : {
         "direction" : "increasing",
         "type" : "linear",
@@ -13,6 +16,7 @@
     "diarrhea" : {
       "title" : "Diarrhea",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
       "pvf" : {
         "direction" : "decreasing",
         "type" : "linear",
@@ -22,6 +26,7 @@
     "dizziness" : {
       "title" : "Dizziness",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
       "pvf" : {
         "direction" : "decreasing",
         "type" : "linear",
@@ -31,6 +36,7 @@
     "headache" : {
       "title" : "Headache",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
       "pvf" : {
         "direction" : "decreasing",
         "type" : "linear",
@@ -40,6 +46,7 @@
     "insomnia" : {
       "title" : "Insomnia",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
       "pvf" : {
         "direction" : "decreasing",
         "type" : "linear",
@@ -49,6 +56,7 @@
     "nausea" : {
       "title" : "Nausea",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
       "pvf" : {
         "direction" : "decreasing",
         "type" : "linear",
@@ -249,4 +257,4 @@
     }
   } ],
   "preferences" : { }
-}
+}
diff --git a/examples/hansen.json b/examples/hansen.json
@@ -1,9 +1,12 @@
 {
   "title": "Hansen et al. 2005 with Placebo as baseline",
+  "description": "Based on Hansen et al. (2005), \"Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder\"",
   "criteria": {
     "HAM-D": {
       "title": "HAM-D",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
+      "description": "Responders on the HAM-D rating scale",
       "pvf": {
         "direction": "increasing",
         "type": "linear",
@@ -13,6 +16,7 @@
     "Diarrhea": {
       "title": "Diarrhea",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
       "pvf": {
         "direction": "decreasing",
         "type": "linear",
@@ -22,6 +26,7 @@
     "Dizziness": {
       "title": "Dizziness",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
       "pvf": {
         "direction": "decreasing",
         "type": "linear",
@@ -31,6 +36,7 @@
     "Headache": {
       "title": "Headache",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
       "pvf": {
         "direction": "decreasing",
         "type": "linear",
@@ -40,6 +46,7 @@
     "Insomnia": {
       "title": "Insomnia",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
       "pvf": {
         "direction": "decreasing",
         "type": "linear",
@@ -49,6 +56,7 @@
     "Nausea": {
       "title": "Nausea",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
       "pvf": {
         "direction": "decreasing",
         "type": "linear",

diff --git a/examples/hypertension.json b/examples/hypertension.json
@@ -1,9 +1,12 @@
 {
-  "title" : "Benefit-risk",
+  "title" : "EMA Edarbi EPAR (hypertension)",
+  "description": "Case study based on the EMA assessment report on Edarbi for the treatment of hypertension. The pivotal trials were pooled to obtain these results.",
   "criteria" : {
     "sbp-mean-trough-clinic-sitting" : {
-      "title" : "SBP mean trough (clinic, sitting)",
+      "title" : "Blood pressure",
+      "description": "Systolic blood pressure (mean trough, clinic, sitting)",
       "scale": [null, null],
+      "unitOfMeasurement": "mm Hg",
       "pvf" : {
         "direction" : "decreasing",
         "type" : "linear",
@@ -12,7 +15,9 @@
     },
     "non-sae" : {
       "title" : "Non-SAE",
+      "description": "Non-serious adverse events",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
       "pvf" : {
         "direction" : "decreasing",
         "type" : "linear",
@@ -21,7 +26,9 @@
     },
     "sae" : {
       "title" : "SAE",
+      "description": "Serious adverse events",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
       "pvf" : {
         "direction" : "decreasing",
         "type" : "linear",
@@ -138,4 +145,4 @@
     }
   } ],
   "preferences" : { }
-}
+}
diff --git a/examples/nemeroff-exact.json b/examples/nemeroff-exact.json
@@ -1,8 +1,11 @@
 {
   "title": "Nemeroff and Thase anti-depressants Example",
+  "description": "Based on C.B. Nemeroff & M.E. Thase (2007), \"A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients\".",
   "criteria": {
     "response": {
       "title": "Treatment Responders",
+      "unitOfMeasurement": "Proportion",
+      "description": "Patients responding to treatment (50% or greater decrease on the HAM-D-21 rating scale)",
       "scale": [0.0, 1.0],
       "pvf": {
         "range": [0.28, 0.63],
@@ -13,6 +16,7 @@
     "nausea": {
       "title": "Nausea ADRs",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
       "pvf": {
         "range": [0.04, 0.50],
         "direction": "decreasing",
@@ -22,6 +26,7 @@
     "insomnia": {
       "title": "Insomnia ADRs",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
       "pvf": {
         "range": [0.08, 0.31],
         "direction": "decreasing",
@@ -31,6 +36,7 @@
     "anxiety": {
       "title": "Anxiety ADRs",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
       "pvf": {
         "range": [0.00, 0.17],
         "direction": "decreasing",

diff --git a/examples/nemeroff.json b/examples/nemeroff.json
@@ -1,9 +1,12 @@
 {
   "title": "Nemeroff and Thase anti-depressants Example",
+  "description": "Based on C.B. Nemeroff & M.E. Thase (2007), \"A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients\".",
   "criteria": {
     "response": {
       "title": "Treatment Responders",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
+      "description": "Patients responding to treatment (50% or greater decrease on the HAM-D-21 rating scale)",
       "pvf": {
         "range": [0.28, 0.63],
         "direction": "increasing",
@@ -13,6 +16,7 @@
     "nausea": {
       "title": "Nausea ADRs",
       "scale": [0.0, 1.0],
+      "unitOfMeasurement": "Proportion",
       "pvf": {
         "range": [0.04, 0.50],
         "direction": "decreasing",
@@ -21,6 +25,7 @@
     },
     "insomnia": {
       "title": "Insomnia ADRs",
+      "unitOfMeasurement": "Proportion",
       "scale": [0.0, 1.0],
       "pvf": {
         "range": [0.08, 0.31],
@@ -30,6 +35,7 @@
     },
     "anxiety": {
       "title": "Anxiety ADRs",
+      "unitOfMeasurement": "Proportion",
       "scale": [0.0, 1.0],
       "pvf": {
         "range": [0.00, 0.17],

diff --git a/examples/rimonabant.json b/examples/rimonabant.json
@@ -1,6 +1,6 @@
 {
   "title": "Rimonabant in type 2 diabetes patients",
-  "description": "Indication: the use of rimonabant as an add-on therapy to an established first-line oral glucose control therapy.\nPatient population: overweight or obese patients with type 2 diabetes mellitus already on metforin or sulphonylurea monotherapy.\nDecision that needs to be taken: marketing authorization",
+  "description": "Indication: the use of rimonabant as an add-on therapy to an established first-line oral glucose control therapy.\nPatient population: overweight or obese patients with type 2 diabetes mellitus already on metforin or sulphonylurea monotherapy.\nDecision that needs to be taken: marketing authorization.",
   "criteria": {
     "Hypo": {
       "title": "Hypoglyceamia",
@@ -17,7 +17,7 @@
       "title": "Fasting glucose",
       "description": "Change in fasting glucose concentrations from baseline.",
       "unitOfMeasurement": "mmol/L",
-      "scale": [-5, 3],
+      "scale": [null, null],
       "pvf": {
         "range": [-2, 2],
         "type": "linear",
@@ -28,7 +28,7 @@
       "title": "SBP",
       "description": "Change in systolic blood pressure from baseline.",
       "unitOfMeasurement": "mm Hg",
-      "scale": [-30, 10],
+      "scale": [null, null],
       "pvf": {
         "range": [-10, 5],
         "type": "linear",
@@ -39,7 +39,7 @@
       "title": "HDL cholesterol",
       "description": "Change in HDL cholesterol from baseline.",
       "unitOfMeasurement": "mmol/L",
-      "scale": [-2, 2],
+      "scale": [null, null],
       "pvf": {
         "range": [0.0, 1.0],
         "type": "linear",
@@ -61,7 +61,7 @@
       "title": "Waist circumference",
       "description": "Change in waist circumference from baseline.",
       "unitOfMeasurement": "cm",
-      "scale": [-15, 5],
+      "scale": [null, null],
       "pvf": {
         "range": [-10, 0],
         "type": "linear",